Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 28, 2026 09:30 ET | Source: Stemline Therapeutics, Inc.

Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant (ORSERDU®) in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Encouraging safety and preliminary efficacy analysis from the elacestrant and capivasertib Phase 1b regimen of the ELEVATE study will be presented.The efficacy data highlight how the combination of...
May 28, 2026 08:30 ET | Source: Oncotelic Therapeutics, Inc.

Sapu Nano Unveils Progress in Deciparticle™ Nanomedicine Platform and AI-Driven Oncology Development at BIO 2026

SAN DIEGO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- via IBN -- Sapu Nano and Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) today announced that Vuong Trieu, Chief Executive Officer,...
May 28, 2026 08:00 ET | Source: Medidata Solutions, Inc.

Medidata’s Next-Gen AI Imaging Solution Delivers Unprecedented Speed and Precision for Clinical Trials

NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions, today unveiled its enhanced, AI-powered imaging solution, within the...
May 28, 2026 07:00 ET | Source: BPGbio

BPGbio to Present Ongoing Phase 2 Study Trial-in-Progress Update of BPM31510 in Newly Diagnosed Glioblastoma at ASCO 2026

BPM31510 is a first-in-class therapeutic targeting tumor metabolism to re-program mitochondrial microenvironment in Warburg-avid tumorsBoth safety profile and efficacy data to be highlighted in...
May 28, 2026 04:00 ET | Source: Anaveon

Anaveon Reports Clinical Benefit of ANV600 in the EXPAND-1 Phase 1 Clinical Trial at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio

Anaveon reports Clinical Benefit of ANV600 in the EXPAND-1 Phase 1 Clinical Trial at ASCO 2026 & actively seeks Partners for its Legacy Oncology Portfolio.
May 27, 2026 09:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting

Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting
May 26, 2026 08:30 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Announces 1-for-10 Reverse Share Split

Grand Cayman, May 26, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi)...
May 26, 2026 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
May 26, 2026 08:00 ET | Source: Artios Pharma

Artios Announces First Patient Dosed in Randomized Phase 2 POLKA Study Evaluating DNA Polymerase Theta Inhibitor ART6043 in gBRCA-mutated HER2-Negative Breast Cancer

Artios announces first patient dosed in randomized Phase 2 POLKA study evaluating DNA Polθ inhibitor ART6043 in gBRCA-mutated HER2-negative breast cancer.
May 26, 2026 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting

SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic...